Player FM - Internet Radio Done Right
Checked 24d ago
Added seven years ago
Content provided by Audioboom and Not So Different: a Podcast from The Center for Biosimilars. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Not So Different: a Podcast from The Center for Biosimilars or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Podcasts Worth a Listen
SPONSORED
T
TED Tech


1 How AI is saving billions of years of human research time | Max Jaderberg 19:15
19:15
Play Later
Play Later
Lists
Like
Liked19:15
Can AI compress the years long research time of a PhD into seconds? Research scientist Max Jaderberg explores how “AI analogs” simulate real-world lab work with staggering speed and scale, unlocking new insights on protein folding and drug discovery. Drawing on his experience working on Isomorphic Labs' and Google DeepMind's AlphaFold 3 — an AI model for predicting the structure of molecules — Jaderberg explains how this new technology frees up researchers' time and resources to better understand the real, messy world and tackle the next frontiers of science, medicine and more. For a chance to give your own TED Talk, fill out the Idea Search Application: ted.com/ideasearch . Interested in learning more about upcoming TED events? Follow these links: TEDNext: ted.com/futureyou TEDAI Vienna: ted.com/ai-vienna Hosted on Acast. See acast.com/privacy for more information.…
S7 Ep4: Escaping the Void: All Things Biosimilars With Craig & G
Manage episode 480739563 series 2161808
Content provided by Audioboom and Not So Different: a Podcast from The Center for Biosimilars. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Not So Different: a Podcast from The Center for Biosimilars or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
REFERENCE
Jeremias S. The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars. February 5, 2025. Accessed May 3, 2025. https://www.centerforbiosimilars.com/view/the-biosimilar-void-90-of-biologics-coming-off-patent-will-lack-biosimilars
Jeremias S. The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars. February 5, 2025. Accessed May 3, 2025. https://www.centerforbiosimilars.com/view/the-biosimilar-void-90-of-biologics-coming-off-patent-will-lack-biosimilars
156 episodes
Manage episode 480739563 series 2161808
Content provided by Audioboom and Not So Different: a Podcast from The Center for Biosimilars. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Not So Different: a Podcast from The Center for Biosimilars or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
REFERENCE
Jeremias S. The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars. February 5, 2025. Accessed May 3, 2025. https://www.centerforbiosimilars.com/view/the-biosimilar-void-90-of-biologics-coming-off-patent-will-lack-biosimilars
Jeremias S. The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars. February 5, 2025. Accessed May 3, 2025. https://www.centerforbiosimilars.com/view/the-biosimilar-void-90-of-biologics-coming-off-patent-will-lack-biosimilars
156 episodes
All episodes
×N
Not So Different: A Podcast from The Center for Biosimilars

1 S7 Ep4: Escaping the Void: All Things Biosimilars With Craig & G 31:55
31:55
Play Later
Play Later
Lists
Like
Liked31:55
REFERENCE Jeremias S. The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars. February 5, 2025. Accessed May 3, 2025. https://www.centerforbiosimilars.com/view/the-biosimilar-void-90-of-biologics-coming-off-patent-will-lack-biosimilars
N
Not So Different: A Podcast from The Center for Biosimilars

1 S7 Ep3: How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment 19:13
19:13
Play Later
Play Later
Lists
Like
Liked19:13
Show notes To learn more about the 10th anniversary of the first FDA biosimilar approval, click here . To learn more about how much biosimilars have saved so far, click here . To read more about Josh's views on the pharmaceutical landscape in 2025, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S7 Ep2: Will the FTC Be More PBM-Friendly Under A Second Trump Administration? 28:55
28:55
Play Later
Play Later
Lists
Like
Liked28:55
Show notes To learn more about the FTC's most recent report on PBMs, click here . To learn more about the FTC's first report on PBMs, click here . To learn more about health care actions taken by the second Trump Administration during it's first month, click here . To learn more about the views of Mehmet Oz, MD (more commonly known as Dr. Oz) on price transparency ahead of his congressional confirmation hearings as President Trump's nominee for HHS Secretary, click here .…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S7 Ep1: Biosimilars in Action: Market Shifts, Legal Insights, and FDA Approvals 14:17
14:17
Play Later
Play Later
Lists
Like
Liked14:17
Show notes 1. Jeremias S. A banner year for biosimilars: The 19 FDA approvals from 2024. The Center for Biosimilars. January 21, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/a-banner-year-for-biosimilars-the-18-fda-approvals-from-2024 2. Jeremias S. FDA approves Celltrion's Avtozma as third tocilizumab biosimilar. The Center for Biosimilars. January 31, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/fda-approves-celltrion-s-avtozma-as-third-tocilizumab-biosimilar 3. Jeremias S. Senators introduce bipartisan legislation to protect skinny labeling. The Center for Biosimilars. January 2, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/senators-introduce-bipartisan-legislation-to-protect-skinny-labeling 4. Jeremias S. FTC releases second report on PBMs meddling in generic drug markets. The Center for Biosimilars. January 19, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/ftc-releases-second-report-on-pbms-meddling-in-generic-drug-markets 5. Santoro C. Earlier patent litigation could accelerate US biosimilar market entry. The Center for Biosimilars. January 9, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/earlier-patent-litigation-could-accelerate-us-biosimilar-market-entry 6. Jeremias S. Welcome Wezlana: the first Stelara biosimilar to launch in the US. The Center for Biosimilars. January 31, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/welcome-wezlana-the-first-stelara-biosimilar-to-launch-in-the-us 7. Jeremias S, Chambers JD. The banking of biosimilars: insights from a leading health economist. The Center for Biosimilars. February 4, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/the-banking-of-biosimilars-insights-from-a-leading-health-economist 8. Jeremias S. The biosimilar void: 90% of biologics coming off patent will lack biosimilars. The Center for Biosimilars. February 5, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/the-biosimilar-void-90-of-biologics-coming-off-patent-will-lack-biosimilars 9. Jeremias S. Biosimilars drive cost savings and achieve 53% market share across treatment areas. The Center for Biosimilars. January 16, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/biosimilars-drive-cost-savings-and-achieve-53-market-share-across-treatment-areas…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep41: The Top 5 Most-Listened to Podcasts of 2024 5:15
5:15
Play Later
Play Later
Lists
Like
Liked5:15
Here are the top 5 episodes of Not So Different from 2024. Number 5: Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved Number 4: Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars Number 3: Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report Number 2: Biosimilars in America: Overcoming Barriers and Maximizing Impact Number 1: Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep40: Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition 5:47
5:47
Play Later
Play Later
Lists
Like
Liked5:47
Show Notes 1. Jeremias S. Skyrizi overtakes Humira: “product hopping” leaves biosimilar market in limbo. The Center for Biosimilars. November 7, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/skyrizi-overtakes-humira-product-hopping-leaves-biosimilar-market-in-limbo 2. Jeremias S. Celltrion sets sights on 2030 with expanded biosimilar portfolio, market reach. The Center for Biosimilars. November 6, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/celltrion-sets-sights-on-2030-with-expanded-biosimilar-portfolio-market-reach 3. Ferreri D. Making the cost of IBD care sustainable. The Center for Biosimilars. November 2, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/making-the-cost-of-ibd-care-sustainable 4. Ferreri D. Achieving PFS in advanced gastric cancer with HLX02 biosimilar, chemotherapy. The Center for Biosimilars. November 23, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/achieving-pfs-in-advanced-gastric-cancer-with-hlx02-biosimilar-chemotherapy 5. Ferreri D. Subcutaneous infliximab CT-P13 superior to placebo as maintenance therapy for IBD . The Center for Biosimilars. November 16, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/subcutaneous-infliximab-ct-p13-superior-to-placebo-as-maintenance-therapy-for-ibd 6. Ferreri D. Challenges, obstacles, and future directions for anti-TNF biosimilars in IBD. The Center for Biosimilars.November 9, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/challenges-obstacles-and-future-directions-for-anti-tnf-biosimilars-in-ibd 7. Jeremias S. Breaking down biosimilar barriers: the patent system.The Center for Biosimilars. November 11, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/breaking-down-biosimilar-barriers-the-patent-system 8. Jeremias S. Breaking down biosimilar barriers: payer and PBM policies. The Center for Biosimilars. November 13, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/breaking-down-biosimilar-barriers-payer-and-pbm-policies 9. Poore D. Breaking down biosimilar barriers: interchangeability. The Center for Biosimilars. November 14, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/breaking-down-biosimilar-barriers-interchangeability 10. The Center for Biosimilars Staff. Webinar: streamlining the regulatory process to advance access to biosimilars. The Center for Biosimilars. November 21, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/webinar-streamlining-the-regulatory-process-to-advance-access-to-biosimilars 11. Jeremias S. Can global policies to boost biosimilar adoption work in the US? The Center for Biosimilars. November 17, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/can-global-policies-to-boost-biosimilar-adoption-work-in-the-us -…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep39: Can Global Policies to Boost Biosimilar Adoption Work in the US? 21:49
21:49
Play Later
Play Later
Lists
Like
Liked21:49
Show notes To learn more about GBW, click here . To check out our coverage of the recent GRx+Biosims conference Craig mentioned, click here . To learn more about product hopping, click here . To read part 1 of our GBW series, click here . To read part 2 of our GBW series, click here . To read part 3 of our GBW series, click here . To hear another episode featuring more of Craig's thoughts on the Biden's administration's impact on the biosimilar industry, click here .…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep38: Biosimilars Development Roundup for October 2024—Podcast Edition 5:20
5:20
Play Later
Play Later
Lists
Like
Liked5:20
Show notes 1. Jeremias S. Strengthening the supply chain: key insights from FDA commissioner Dr Robert Califf. The Center for Biosimilars®. October 25, 2024. Accessed November 1, 2024. https://www.centerforbiosimilars.com/view/strengthening-the-supply-chain-key-insights-from-fda-commissioner-robert-califf 2. Jeremias S. FDA and industry experts unpack biosimilar device requirements. The Center for Biosimilars. October 23, 2024. Accessed November 1, 2024. https://www.centerforbiosimilars.com/view/fda-and-industry-experts-unpack-biosimilar-device-requirements 3. Jeremias S. Calling for Unified Biosimilar Standards, Stronger Education at GRx+Biosims. The Center for Biosimilars. October 23, 2024. Accessed November 1, 2024. https://www.centerforbiosimilars.com/view/calling-for-unified-biosimilar-standards-stronger-education-at-grx-biosims 4. Jeremias S. Unifying standards: the need for streamlined biosimilar development. The Center for Biosimilars. October 22, 2024. Accessed November 1, 2024. https://www.centerforbiosimilars.com/view/unifying-standards-the-need-for-streamlined-biosimilar-development 5. Jeremias S. Enhancing Adoption of Infused Biosimilars for a Sustainable Future. The Center for Biosimilars. October 30, 2024. Accessed November 1, 2024. https://www.centerforbiosimilars.com/view/enhancing-adoption-of-infused-biosimilars-for-a-sustainable-future 6. Jeremias S. IQVIA webinar: enhancing regulatory strategies for biosimilars and generics. The Center for Biosimilars. October 14, 2024. Accessed November 1, 2024. https://www.centerforbiosimilars.com/view/iqvia-webinar-enhancing-regulatory-strategies-for-biosimilars-and-generics…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep37: Biosimilars Policy Roundup for September 2024—Podcast Edition 7:52
7:52
Play Later
Play Later
Lists
Like
Liked7:52
Show notes 1. FDA Approves Pavblu for Retinal Conditions 2. AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1 3. Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys 4. The Future of Biosimilar Gene Therapies: Key Issues and Potential 5. IRA Reimbursement Impact on Biosimilars Minimal Despite Rising Market Share 6. The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings 7. France Study Finds High Patient Satisfaction With Adalimumab Biosimilar Treatment for IBD…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep36: Biosimilars Business Roundup for August 2024—Podcast Edition 5:22
5:22
Play Later
Play Later
Lists
Like
Liked5:22
Show notes 1. Sandoz Reports 29% Growth in Biosimilar Revenues for First Half of 2024 2. Pure-Play Biosimilar Company Reports 10-Fold Revenue Increase for First Half of 2024 3. Formycon Reports €26.9 Million Revenue for First Half 2024, Driven by Biosimilars 4. CMS Announces New Drug Prices Under the IRA, Including for Stelara and Enbrel 5. FDA Approves Biosimilar Enzeevu for Eye Conditions 6. Manitoba Adopts Biosimilar Switching Policy 7. Eye on Pharma: Celltrion, Costco Partnership; Amgen Sues Samsung Bioepis; Denosumab Results 8. Vizient Report Projects Price Inflation for Originators With Biosimilars in the Pipeline…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep35: Biosimilars Policy Roundup for July 2024—Podcast Edition 5:12
5:12
Play Later
Play Later
Lists
Like
Liked5:12
Show notes 1. FDA Approves Samsung Bioepis’ Pyzchiva, a Biosimilar to Stelara 2. Ahzantive Receives FDA Approval as New Eylea Biosimilar 3. FDA Approves Epysqli as Second Soliris Biosimilar 4. BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed 5. Biosimilars and Employers: Strategies for Success 6. Learning the Lingo of Biologics and Biosimilars Is Critical 7. Singapore Experience Shows Benefits of Value-Driven Strategies in Generating Biosimilar Savings 8. Approximately Half of Patients Demonstrated Poor Health Literacy Prior to Biosimilar Switch…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep34: Biosimilars in America: Overcoming Barriers and Maximizing Impact 27:23
27:23
Play Later
Play Later
Lists
Like
Liked27:23
Show notes To learn more about Cencora and their efforts, click here . To learn more about the Inflation Reduction Act's impact on biosimilars, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep33: Biosimilars Oncology Roundup for June 2024—Podcast Edition 6:14
6:14
Play Later
Play Later
Lists
Like
Liked6:14
Show notes 1. Biosimilars Check-In: Application Acceptances, European Approvals, New Partnerships 2. Overcoming Economic, Noneconomic Barriers to Biosimilar Adoption in Oncology 3. EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions 4. New Data Show Safety of Ado-Trastuzumab, Trastuzumab Biosimilars in HER2+ Cancers 5. ASCO Posters Reflect on Reimbursement Trends, Combination Therapies Involving Biosimilars 6. ASCO 2024 Posters Showcase Positive Data on Denosumab, Pegfilgrastim Biosimilars 7. Authors Spotlight Long-Term Solutions to Ensure Biosimilar Market Sustainability 8. Part 2: Unlocking the Potential of Biosimilars to Improve Health Equity…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep32: Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved 27:45
27:45
Play Later
Play Later
Lists
Like
Liked27:45
To learn more about the approval of denosumab-bddz, click here . To watch Curtis and Edgerton speak on the approval of denosumab-bddz and osteoporosis treatment, click here . To learn more about the ROSALIA study (NCT05405725), click here . Extra content: To read more about the Biosimilars Council position paper on how to improve biosimilar development, click here .…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep31: Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition 5:16
5:16
Play Later
Play Later
Lists
Like
Liked5:16
Show notes FDA Approves High-Concentration Cyltezo Eye on Pharma: Simlandi US Launch; Ranibizumab Partnership; Expanded Access for Adalimumab Biosimilars DDW 2024 Posters Evaluate Safety, Efficacy, Impact of BMI on Zymfentra Use Posters Demonstrate Switching Safety Between Originator, Biosimilar Infliximab in IBD New Evidence Confirms Safe Biosimilar-to-Biosimilar Switching Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep30: Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report 14:53
14:53
Play Later
Play Later
Lists
Like
Liked14:53
Show notes To read our coverage of the Cardinal Health report, click here . To read the full report, click here . To check out The Center for Biosimilars coverage of Festival of Biologics USA, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep29: Biosimilars Policy Roundup for April 2024—Podcast Edition 5:07
5:07
Play Later
Play Later
Lists
Like
Liked5:07
Show notes FDA Approves Henlius’ Trastuzumab Biosimilar, Hercessi Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar AON Saves Over $243 Million With High Biosimilar Adoption Julie Reed: Why 2024 Is Important for Biosimilars The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion Review Highlights Most Popular European Policies to Boost Biosimilar Uptake…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep28: Biosimilars Dermatology Roundup for March 2024—Podcast Edition 4:43
4:43
Play Later
Play Later
Lists
Like
Liked4:43
Show notes AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars Posters From AMCCBS and AAD Showcase New Technology for Biosimilar Uptake, Barriers to Self-Injectable Biologics Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake Adalimumab Expenditures in Countries With and Without Available Biosimilars Review: Real-World Evidence Confirms Effectiveness and Safety of Adalimumab Biosimilar SB5 Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs Cardinal Health Report Showcases Biosimilar Growth, Provider and Payer Evolution, and More…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep27: Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars 20:34
20:34
Play Later
Play Later
Lists
Like
Liked20:34
Show notes To read more of Ha Kung's thoughts on the US patent system and its role in the biosimilar landscape, click here . To learn more about Congress' role in addressing AbbVie's alleged anticompetitive practices regarding adalimumab products, click here . To learn more about the suit filed by CareFirst BlueCross BlueShield regarding ustekinumab biosimilar delays, click here . To learn more about the settlements that have resulted in the market delay of ustekinumab biosimilars, click here . To learn more about lawsuits involving AbbVie that led to the delayed market entrance of adalimumab biosimilars, click here . To learn more about what types of patents are at most to blame for biosimilar market delays, click here .…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep26: Biosimilars Rheumatology Roundup for February 2024—Podcast Edition 5:03
5:03
Play Later
Play Later
Lists
Like
Liked5:03
Show notes FDA Approves 10th Adalimumab Biosimilar, Simlandi Samsung Bioepis Announces New Biosimilar Partnership, Regulatory Updates Vizient Report Emphasizes Biosimilar Successes, Impact of Inflation on Drug Spend Eye on Pharma: VA Picks Hadlima; Biocon, Sandoz Partnership; A Stelara Settlement Abroad Eye on Pharma: Celltrion Biosimilars Win Tenders; Oral Ustekinumab Device Passes Phase 1 Trial Analyzing Safety of Switching From Originators to Biosimilars: A Meta-Analysis of 21 Trials Adalimumab Treatment May Impact Antibody Levels After COVID-19 Vaccination…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep25: Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024 25:42
25:42
Play Later
Play Later
Lists
Like
Liked25:42
For more information on BsUFA III, click here . For more information on the 1-year anniversary of adalimumab biosimilars in the US, click here . To listen to more of Julie Reed's thoughts on the US biosimilar industry and streamlining development, click here . To learn more about the Biosimilars Forum, click here .…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep24: Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition 5:06
5:06
Play Later
Play Later
Lists
Like
Liked5:06
Happy Birthday Adalimumab Biosimilars: Reflecting on the First Year of US Competition EMA Approves First Ustekinumab Biosimilar, Uzpruvo Eye on Pharma: Fresh Biosimilar Lawsuits; FDA to Review Ustekinumab, Denosumab Biosimilars IQVIA Report Flags Challenges With Biosimilar Access, Savings Throughout Europe IQVIA Projects $192 Billion Loss for Originators by 2028 Thanks to Biosimilar, Generic Competition Report: Varied Biosimilar Uptake Speeds Pose Missed Opportunities for Cost Savings Biosimilar SB5 Matches Originator in Safety, Efficacy for Inflammatory Diseases After Switching Postapproval Pharmacovigilance Review Confirms Comparable Safety Between Sandoz Biosimilars, Originators…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep23: A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond 19:32
19:32
Play Later
Play Later
Lists
Like
Liked19:32
Show notes To learn more about the prospect for Neulasta OnPro biosimilars, click here . To learn more about how the IRA will impact biosimilars, click here . To learn more about the dual-pricing strategy being used for adalimumab biosimilars, click here . To hear Brian's insight into how the ophthalmology biosimilar industry is developing, click here . To listen to previous Not So Different episodes featuring more of Brian's insight into how the adalimumab market will develop and biosimilar pricing trends, click here or here .…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep22: The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur 12:15
12:15
Play Later
Play Later
Lists
Like
Liked12:15
Show notes To learn more about the FDA approval of Zymfentra, click here . To learn more about the results from the LIBERTY trials, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep21: Biosimilar Oncology Roundup for November 2023—Podcast Edition 5:09
5:09
Play Later
Play Later
Lists
Like
Liked5:09
Show notes Webinar: Where Do Biosimilars Fit Into the Cancer Treatment Puzzle? Part 1: Oncology Biosimilars Offer Comparable Benefits to Originators at Lower Prices Part 2: French Study Finds Trastuzumab Biosimilar Program Could Generate Meaningful Savings Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe Denosumab Biosimilar Demonstrates Positive Safety Results in Chinese Study Eye on Pharma: Denosumab Biosimilar Data; COA Forms New Committee; IGBA and WHO Collaborate Similar Safety Profiles of Biosimilar, Reference Pegfilgrastim Found in Clinical Studies Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep20: Global Biosimilars Week: Dr Fran Gregory Explores the Growing Oncology Biosimilar Space, Previews Future 26:40
26:40
Play Later
Play Later
Lists
Like
Liked26:40
Show notes For more information on Global Biosimilars Week, click here . To read our article series in honor of Global Biosimilars Week, you can check out part 1 , part 2 , and part 3 here. To watch the webinar The Center for Biosimilars collaborated with IGBA for Global Biosimilars Week, click here .…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep19: Biosimilar Business Roundup for October 2023—Podcast Edition 5:13
5:13
Play Later
Play Later
Lists
Like
Liked5:13
FDA Approves First Subcutaneous Infliximab Product Abrilada Approved as Second Interchangeable Humira Biosimilar Eye on Pharma: New GI Data and Byooviz Interchangeability Propel Biosimilars Into the Future Biosimilars Check-In: BI Launches Unbranded Adalimumab; New Omalizumab Deal; CRL for Insulin Aspart Eye on Pharma: Another CRL for Alvotech; Cimerli’s Growing Market Share; BBCIC Awarded Grant Samsung Bioepis Presents Positive Phase 3 Data on Aflibercept Candidate AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep18: Biosimilars Regulatory Roundup For September 2023– Podcast Edition 4:18
4:18
Play Later
Play Later
Lists
Like
Liked4:18
Show Notes House Committee Hearing Addresses PBMs, Anticompetitive Drug Pricing Tactics Part 2: FDA Workshop Shares Manufacturer Perspective on the Value of Clinical Efficacy Testing Part 1: FDA Workshop Highlights Global Regulatory View on Biosimilar Development Part 3: BioRationality—FDA Webinar on Biosimilars Efficacy Testing Marks Major Step Forward Alvotech’s Stelara Biosimilar Approved in Japan EC Approves First MS Biosimilar; Coherus Receives CRL for Neulasta Onpro Competitor European Commission Approves First Aflibercept Biosimilar Regulatory Updates From Around the Globe Provide Hope for Biosimilars…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep17: Dr. Fran Gregory's Sizes Up the US Adalimumab Market: Will Biosimilars See Success? 22:21
22:21
Play Later
Play Later
Lists
Like
Liked22:21
To read more about Dr. Gregory's commentary piece, click here . To read more about Cardinal Health's 2023 Biosimilars Report, click here . To learn more about adalimumab biosimilars, click here . To learn more about the adalimumab biosimilars that have launched so far in the US: Click here for the launch of Amjevita Click here for the launches of Hyrimoz, Hadlima, Yusimry, and Cyltezo Click here for the launch of Yuflyma Click here for the launches of Idacio and Hulio…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep16: Biosimilars Business Roundup For August 2023– Podcast Edition 5:06
5:06
Play Later
Play Later
Lists
Like
Liked5:06
Show Notes FDA Approves First MS Biosimilar Stelara and Enbrel Chosen for IRA Price Negotiation Biocon Biosimilar Quarterly Sales Up 106% STADA Earnings Project Record Breaking Profits for 2023 Despite Global Increase in Amjevita Sales, US Sales Dropped 63% Authors Suggest Major Policy Shifts to Boost Biosimilar Development, Accessibility Cardinal Health Exec: How Adalimumab Biosimilars Can Reshape the US Health Care Industry…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep15: How Streamlining Development Can Save the US Biosimilar Industry 24:13
24:13
Play Later
Play Later
Lists
Like
Liked24:13
Show notes To read CFB's analysis of the paper, click here . To view the full version of the paper, click here . To learn more about the Biosimilars Forum and its members, click here . To read the IQVIA report cited in the paper, click here . To read the IQVIA report cited in the paper, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep14: Biosimilars Immunology Roundup for July 2023- Podcast Edition 4:32
4:32
Play Later
Play Later
Lists
Like
Liked4:32
Show Notes First Round of Adalimumab Biosimilar Launches in July Celltrion Launches Yuflyma on the US Market US Welcomes Idacio, Hulio to the Adalimumab Biosimilar Market Will the Entry of Adalimumab Biosimilars to the US Market Successfully Lower Spending? Contributor: Self-Administered Biosimilars Are Coming Quickly—Is Your Clinic Ready? Despite Steep Discounts, Humira Biosimilars Are Priced More Than Original Originator Price Price Reductions of TNF Inhibitors Across Europe After First and Second Biosimilar Launches Multiple Infliximab Biosimilar Switches Were Safe, Effective Adalimumab Biosimilar Improved Symptoms for up to 48 Weeks in Ankylosing Spondylitis Biosimilar, Innovator Romiplostim Comparably Safe and Effective…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep13: Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment 16:26
16:26
Play Later
Play Later
Lists
Like
Liked16:26
Show notes To learn more about the adalimumab products that have launched in the US so far, click here , here , here , or here . Crohn's & Colitis Educational Resources: Biosimilars: What You Should Know What is a Biosimilar Video
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep12: Biosimilars Business Roundup for June 2023—Podcast Edition 4:31
4:31
Play Later
Play Later
Lists
Like
Liked4:31
Show notes Mark Cuban’s Online Pharmacy Partners With Coherus Biosciences for Humira Biosimilar Roundup: Coherus Resolves AbbVie Dispute; Bio-Thera Solutions and Celltrion Expand Respective Partnerships Eye on Pharma: First PBM to Cover Yusimry; Celltrion to Test Ocrevus Biosimilar; Another Stelara Settlement The Age of Adalimumab Is Upon Us: How Stakeholders Can Prepare Alvotech, Advanz Pharma Extend Partnership for Biosimilars in Europe Medicare 340B Program May Be Reducing Biosimilar Uptake Sandoz Roadmap Aims to Increase Worldwide Biosimilar Adoption by 2030…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep11: Biosimilars Immunology Roundup for May 2023—Podcast Edition 4:45
4:45
Play Later
Play Later
Lists
Like
Liked4:45
Show Notes FDA Approves Celltrion’s Yuflyma, the Ninth Adalimumab Biosimilar Celltrion Launches Biobetter in Brazil, Shares Phase 3 Plan for MS Biosimilar Amgen’s Stelara Biosimilar Delayed Until 2025 After Settling With J&J Dr Colby Evans: The Managed Care Perspective on Biosimilars in Immunology Dr Vibeke Strand: The Current State of Immunology Biosimilars and the Promise of Future Savings Samsung Bioepis Report Correlates Biosimilar Pricing Changes With Market Adoption Biosimilars Business News Recap: A New Partnership; Celltrion Wins Tenders Tocilizumab Biosimilar LZM008 Demonstrates PK Equivalence in Healthy Participants RWE: Rituximab Biosimilar GP2013 Effective in Patients With RA After Switching From Originator…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep10: What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends 19:19
19:19
Play Later
Play Later
Lists
Like
Liked19:19
To learn more about Tasmina's Asembia 2023 presentation, click here . Check out the full AmerisourceBergen Biosimilar pipeline report . To listen to Brian's past appearance on Not So Different, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep9: Dr. Vibeke Strand: The Current State of Immunology Biosimilars and the Promise of Future Savings 13:10
13:10
Play Later
Play Later
Lists
Like
Liked13:10
Show notes To read all the articles within the supplement, click here . To read the article references in this episode, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep8: Biosimilars Rheumatology Roundup for April 2023—Podcast Edition 4:42
4:42
Play Later
Play Later
Lists
Like
Liked4:42
Biosimilars Check In: Vegzelma Launch, BLA Acceptances, China Approval FDA Issues Another CRL for Alvotech’s Adalimumab Biosimilar Multiple Infliximab Biosimilar Switches Appear Safe, Effective for Patients With IBD Study on Nonmedical Switching for Adalimumab Biosimilars Warns About Nocebo Effect Spherix Global Insights: Despite High Awareness, Provider Comfort With Adalimumab Biosimilars Is Low Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars Study Reveals Factors That Dissuade Commercial Plans From Covering Biosimilars…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep7: Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars 18:40
18:40
Play Later
Play Later
Lists
Like
Liked18:40
To learn more about biosimilars to treat RA, click here . To learn more about rheumatologists’ perceptions about RA biosimilars, click here . To learn more about incentives for prescribing biosimilars, click here . To learn more about infliximab biosimilar adoption, click here . To learn more about the influx of adalimumab biosimilars to the US market, click here . To learn more about ustekinumab biosimilars, click here .…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep6: Biosimilars Policy Roundup for March 2023—Podcast Edition 3:53
3:53
Play Later
Play Later
Lists
Like
Liked3:53
Show notes Canadian Province Newfoundland and Labrador Adds Biosimilar Switching Policy Yukon Becomes Tenth Canadian Jurisdiction to Add Biosimilars Switching Policy Policy Recommendations for Improving Biosimilar Uptake in Belgium Researchers Recommend Improvements for China’s Biosimilar Regulatory Policies Dr Ivo Abraham Column: The 2022 WHO Biosimilar Guidelines—Loosening the Reins or Changing the Track? Part 2 The Increasing Access to Biosimilars Act of 2023 Introduced to Congress Published Data Coupled With Real-world Evidence Show Safety of Biosimilar-to-Biosimilar Switching Uptake Barriers Will Deter Future Competitors From Investing in Biosimilars, Julie Reed Warns…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep5: How Community Oncologists Can Break Down Biosimilar Adoption Barriers 13:55
13:55
Play Later
Play Later
Lists
Like
Liked13:55
Show notes To listen to our podcast with Cheryl Vaughn, vice president of clinical services at McKesson, discussed how McKesson's Intrafusion service helps manage infusion sites and aids in the administration of complex biologic drugs, including biosimilars, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep4: Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition 5:09
5:09
Play Later
Play Later
Lists
Like
Liked5:09
Show notes Eye on Pharma: Formycon Aflibercept Data; Sandoz CHMP Nod; Henlius Daratumumab Study https://www.centerforbiosimilars.com/view/eye-on-pharma-formycon-aflibercept-data-sandoz-chmp-nod-henlius-daratumumab-study Report: Over 60% of Providers Plan to Only Prescribe Interchangeable Adalimumab Biosimilars https://www.centerforbiosimilars.com/view/report-over-60-of-providers-plan-to-only-prescribe-interchangeable-adalimumab-biosimilars IQVIA: US Spending on Biosimilars to Reach $129 Billion Over Next 5 Years https://www.centerforbiosimilars.com/view/iqvia-us-spending-on-biosimilars-to-reach-129-billion-over-next-5-years Vizient Report Predicts Over 3% Inflation Rate for Biologics https://www.centerforbiosimilars.com/view/vizient-report-predicts-over-3-inflation-rate-for-biologics On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars https://www.centerforbiosimilars.com/view/on-the-come-up-what-vizient-s-report-says-about-inflation-and-biosimilars Patients With RA, IBD Trust Specialists’ Biologic and Biosimilar Recommendations https://www.centerforbiosimilars.com/view/patients-with-ra-ibd-trust-specialists-biologic-and-biosimilar-recommendations Study: Higher Adherence Rates Among Users of the Remicade vs Infliximab Biosimilars https://www.centerforbiosimilars.com/view/study-higher-adherence-rates-among-users-of-the-remicade-vs-infliximab-biosimilars…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep3: On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars 13:25
13:25
Play Later
Play Later
Lists
Like
Liked13:25
Show notes To learn more about Vizient’s Pharmacy Outlook Report, click here . To read Dr. Dolan’s paper “Opportunities and Challenges in Biosimilar Uptake in Oncology published in The American Journal of Managed Care ®, click here . To read Dr. Dolan’s paper “Evolving Practices in Managing Costly Immunotherapy” published in The American Journal of Managed Care®, click here .…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep2: Biosimilars Rheumatology Roundup for January 2023—Podcast Edition 5:32
5:32
Play Later
Play Later
Lists
Like
Liked5:32
Show notes US Welcomes First Adalimumab Biosimilar, Amjevita https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita Canada Approves High-Concentration Humira Biosimilar https://www.centerforbiosimilars.com/view/canada-approves-high-concentration-humira-biosimilar Celltrion Submits BLA for Infliximab Biobetter https://www.centerforbiosimilars.com/view/celltrion-submits-bla-for-infliximab-biobetter FDA Accepts BLA for Alvotech Ustekinumab Biosimilar https://www.centerforbiosimilars.com/view/fda-accepts-bla-for-alvotech-ustekinumab-biosimilar Biosimilars Check-in: Approval in Saudi Arabia, Launch in Republic of Korea, Dr. Reddy’s Completes Study https://www.centerforbiosimilars.com/view/biosimilars-check-in-approval-in-saudi-arabia-launch-in-republic-of-korea-dr-reddy-s-completes-study China's NMPA Approves Tocilizumab Biosimilar https://www.centerforbiosimilars.com/view/china-s-nmpa-approves-tocilizumab-biosimilar US Welcomes First Adalimumab Biosimilar, Amjevita https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita Study: Does Adalimumab Lose Effectiveness After Switching to a Biosimilar? https://www.centerforbiosimilars.com/view/study-does-adalimumab-lose-effectiveness-after-switching-to-a-biosimilar- Phase 1 Trial for Alvotech Golimumab Biosimilar Begins https://www.centerforbiosimilars.com/view/phase-1-trial-for-alvotech-golimumab-biosimilar-begins Case Study: Treatment With Adalimumab Biosimilar Resolved Pediatric Scalp, Nail Psoriasis https://www.centerforbiosimilars.com/view/case-study-treatment-with-adalimumab-biosimilar-resolved-pediatric-scalp-nail-psoriasis…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S6 Ep1: Seeing Eye to Eye: FDA's Dr Sarah Yim Discusses Efforts to Increase Confidence in Ophthalmology Biosimilars 13:50
13:50
Play Later
Play Later
Lists
Like
Liked13:50
Show notes: To check out part 1 of this interview series (written Q&A with Samsung Bioepis’ Kyung-Ah Kim), click here . Coming soon, part 3 will be a video interview about the initial market response to ophthalmology biosimilars and how industry leaders can work together to increase uptake. To learn more about the approval of Cimerli, click here . To learn more about ophthalmology biosimilars, click here . To learn more about interchangeability, click here . To learn more about clinical efficacy testing, click here . To learn more about our LinkedIn Live event on ophthalmology biosimilars, you can read more here or watch the full discussion here . To check out the FDA’s overview page on biosimilars, click here . To check out the FDA’s patient-focused biosimilar education materials (English and Spanish versions), click here . To check out the FDA’s biosimilar education materials for health care professionals, click here . For more information on the FDA's biosimilar curriculum, click here . For more information on the FDA's free CE courses on biosimilars, click here and use the filter function to select biosimilars.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S5 Ep14: Goodbye 2022—The Top 10 Biosimilars Stories of the Year 5:37
5:37
Play Later
Play Later
Lists
Like
Liked5:37
Top 10 stories of the year: 10. FDA Approves Stimufend, the US’ Sixth Pegfilgrastim Biosimilar 9. Contributor: No Animal Testing of Biosimilars—US Congress Begins Amendment to BPCIA 8. AbbVie Settles ITC Case With Alvotech; Humira Biosimilar to Launch July 2023 7. Review: Biobetters and Biosimilars Set to Emerge in Ophthalmology 6. Report: Biosimilar Competition in Europe 5. Part 1: Biosimilars to Bring a Bumper Crop of Adalimumab Options - For the whole series, click here . 4. FDA Accepts BLAs Supporting Interchangeability From Alvotech, Pfizer for Biosimilars to Humira 3. Samsung Bioepis and Organon Seek to Enter the Market for High-Concentration Adalimumab 2. FDA Approves High-Concentration Formulation of Samsung Bioepis’ Humira Biosimilar 1. Teva Announces US Launch of Lenalidomide, Generic of Revlimid Top 5 podcast episodes of the year: 5. How Health Policy Can Impact Adoption for Adalimumab Biosimilars 4. New Biosim on the Block: Dr Sonia Oskouei Discusses the US Launch of Byooviz, the First Ophthalmology Biosimilar 3. What Amgen’s Biosimilar Trends Report Says About the Future of Biosimilars 2. How Health Policies May Take Shape in a Post-Humira-Exclusive Adalimumab Market 1. What Will Year 1 Look Like for Adalimumab Biosimilars?…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S5 Ep13: New Year, New Hurdles: What's in Store for Biosimilars in 2023 18:12
18:12
Play Later
Play Later
Lists
Like
Liked18:12
To read more about adalimumab biosimilars, click here . To read more about ophthalmology biosimilars, click here . To learn more about the Inflation Reduction Act’s impact on biosimilars, click here . To read more about the reauthorization of the Biosimilars User Fee Amendment, click here . To learn more about interchangeability, click here .…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S5 Ep12: Biosimilars Regulatory Roundup for November 2022—Podcast Edition 4:34
4:34
Play Later
Play Later
Lists
Like
Liked4:34
Show notes Rezvoglar Becomes Second Interchangeable Insulin Biosimilar Biosimilar Business Recap: Progress for Insulin in Europe, Canada; Biocon Biologics' Viatris Acquisition Completed The European Union Gains Another Ranibizumab Biosimilar Alvotech Snags Australian Approval for Adalimumab Biosimilar Biosimilar Check-in: PBM to Cover Adalimumab Biosimilars; World’s First Denosumab Biosimilar; Organon Launches in Canada Senator Introduces Bill to Rid Switching Study Requirements for Interchangeability BioRationality: A Dr Sarfaraz Niazi Column—FDA Launches Biosimilar Regulatory Science Program AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S5 Ep11: What Amgen’s Biosimilar Trends Report Says About the Future of Biosimilars 19:53
19:53
Play Later
Play Later
Lists
Like
Liked19:53
Show notes: To read more about Amgen’s Biosimilar Trends Report, click here . To learn more about the Inflation Reduction Act’s impact on biosimilars, click here . To see more of Chad’s takeaways from older version of Amgen’s Biosimilar Trends Report, click here . To learn more about tender systems, click here . To check out the last episode of Not So Different, click here .…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S5 Ep10: AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars? 19:39
19:39
Play Later
Play Later
Lists
Like
Liked19:39
This episode is made in conjunction with the third annual Global Biosimilars Week, a biosimilar awareness campaign hosted by the International Generic and Biosimilar Association (IGBA) from November 14 through November 18. The Center for Biosimilars is a proud media partner for Global Biosimilars Week and you can check all our social media pages to view our coverage of the event. To learn more about Global Biosimilars Week, click here . To learn more about BsUFA III, click here . To learn more about the Inflation Reduction Act, click here . To learn more about President Biden’s executive order, click here . To learn more about President Biden’s support for biotechnology, click here . To learn more about efforts to investigate pharmacy benefit managers, click here . To learn more about the FDA’s recent workshop, click here . To learn more about the FDA’s updated guidance on interchangeability, click here . To learn more about the approval of Cimerli, click here , and to learn more about the controversy surrounding it, click here .…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S5 Ep10: Biosimilars Policy Roundup for October 2022—Podcast Edition 5:22
5:22
Play Later
Play Later
Lists
Like
Liked5:22
Show notes Saskatchewan Becomes Sixth Canadian Province to Implement a Biosimilar Switching Policy Advocacy Organization Calls for Ontario to Switch Patients to Biosimilars BioRationality: a Dr Sarfaraz Niazi Column—The EMA Declares Biosimilars Interchangeable Biden Authorizes Update to the Biosimilar User Fee Act Through 2027 New Bill Aims to Remove Barriers to Interchangeable Biosimilars Amgen Report: Biosimilars Have Saved $21 Billion in 6 Years It’ll Take a Village: Collaborative Efforts Needed to Increase Ophthalmology Biosimilar Uptake Order of Operations: Managing Biosimilars While Maintaining Operational Efficiency Dr Ryan Haumschild: What Health Systems Can Learn From Emory Healthcare's Biosimilar Strategy…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S5 Ep9: Order of Operations: Managing Biosimilars While Maintaining Operational Efficiency 13:28
13:28
Play Later
Play Later
Lists
Like
Liked13:28
Show notes: To read more of Kathy’s thoughts on the practice perspective regarding biosimilars, click here . To learn more about automatic substitution policies, click here . To learn more about some of the challenges clinicians could face next year as adalimumab biosimilars enter the market, click here . To learn more about prescription behaviors regarding biosimilars, click here . To listen to another podcast episode on a tool that can improve infusion center efficiency, click here .…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S5 Ep8: Biosimilars Oncology Roundup for September 2022—Podcast Edition 4:18
4:18
Play Later
Play Later
Lists
Like
Liked4:18
Show notes FDA Approves Stimufend, the US’ Sixth Pegfilgrastim Biosimilar https://www.centerforbiosimilars.com/view/fda-approves-stimufend-the-us-sixth-pegfilgrastim-biosimilar FDA Approves Celltrion Biosimilar for Avastin, Vegzelma https://www.centerforbiosimilars.com/view/fda-approves-celltrion-biosimilar-for-avastin-vegzelma Oncology, Ophthalmology Biosimilars Progress in Europe https://www.centerforbiosimilars.com/view/oncology-ophthalmology-biosimilars-progress-in-europe Biosimilars Check-In: Canada Approves Third Etanercept; Prestige Withdraws Trastuzumab Application https://www.centerforbiosimilars.com/view/biosimilars-check-in-canada-approves-third-etanercept-prestige-withdraws-trastuzumab-application Coherus Rep Shares Competition Strategy for Adalimumab, Pegfilgrastim Biosimilars https://www.centerforbiosimilars.com/view/coherus-rep-previews-interchangeable-ranibizumab-adalimumb-launches-on-pro-competitor?seriesVid=5 Policy Harmonization, Clarification Could Aid Biosimilar Uptake Efforts https://www.centerforbiosimilars.com/view/policy-harmonization-clarification-could-aid-biosimilar-uptake-efforts Upcoming WHO Guideline Changes May Reduce Data Requirements for Biosimilar Development https://www.centerforbiosimilars.com/view/upcoming-who-guideline-changes-may-reduce-data-requirements-for-biosimilar-development Dr Ivo Abraham Column: When More May Yield Less—Price Erosion of Biosimilars Following US Market Entry https://www.centerforbiosimilars.com/view/dr-ivo-abraham-column-when-more-may-yield-less-price-erosion-of-biosimilars-following-us-market-entry…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S5 Ep7: How Heath Policy Can Impact Adoption for Adalimumab Biosimilars 22:59
22:59
Play Later
Play Later
Lists
Like
Liked22:59
This special episode is part of a larger series called “WHEN CHOICE ARRIVES: Competition & Consequences,” consisting of 4 articles and 2 podcasts. The series delves into everything that stakeholders need to know as everyone prepares for the 2023 introduction of adalimumab biosimilars. To read part 1 of this series, “Biosimilars to Bring a Bumper Crop of Adalimumab Options,” click here . To read part 2 of this series, “For Patients and Employers, 2023 Means a Changed Landscape,” click here . To read part 3 of this series, “How Adalimumab Biosimilars Will Impact Clinicians,” click here . To listen to the other podcast in this series, “What Will Year 1 Look Like for Adalimumab Biosimilars?” click here .…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S5 Ep6: What Will Year 1 Look Like for Adalimumab Biosimilars? 22:53
22:53
Play Later
Play Later
Lists
Like
Liked22:53
This special episode is part of a larger series called “WHEN CHOICE ARRIVES: Competition & Consequences,” consisting of 4 articles and 2 podcasts. The series delves into everything that stakeholders need to know as everyone prepares for the 2023 introduction of adalimumab biosimilars. To read part 1 of this series, “Biosimilars to Bring a Bumper Crop of Adalimumab Options,” click here . To read part 2 of this series, “For Patients and Employers, 2023 Means a Changed Landscape,” click here . To read part 3 of this series, “How Adalimumab Biosimilars Will Impact Clinicians,” click here . To listen to the other podcast in this series, “What Will Year 1 Look Like for Adalimumab Biosimilars?” click here .…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S5 Ep5: Biosimilars Regulatory Roundup for August 2022—Podcast Edition 4:37
4:37
Play Later
Play Later
Lists
Like
Liked4:37
Opinion: Impact of Inflation Reduction Act 2022—Addressing Critics https://www.centerforbiosimilars.com/view/opinion-impact-of-inflation-reduction-act-2022-addressing-critics Opinion: The Inflation Reduction Act is a Step Backward for Biosimilar Competition https://www.centerforbiosimilars.com/view/opinion-the-inflation-reduction-act-is-a-step-backward-for-biosimilar-competition $35 Insulin Cap for Private Sector Blocked From Budget Reconciliation Bill https://www.centerforbiosimilars.com/view/-35-insulin-cap-for-private-sector-blocked-from-budget-reconciliation-bill European Commission Approves Second Lucentis Biosimilar https://www.centerforbiosimilars.com/view/european-commission-approves-second-lucentis-biosimilar FDA Approves Coherus’ Cimerli as Interchangeable Biosimilar to Ranibizumab https://www.centerforbiosimilars.com/view/fda-approves-coherus-cimerli-as-interchangeable-biosimilar-to-ranibizumab FDA Approves High-Concentration Formulation of Samsung Bioepis’ Humira Biosimilar https://www.centerforbiosimilars.com/view/fda-approves-high-concentration-formulation-of-samsung-bioepis-humira-biosimilar Eye on Pharma: Celltrion Aims for Adalimumab Interchangeability; Phase 3 Results for Ustekinumab Biosimilar https://www.centerforbiosimilars.com/view/eye-on-pharma-celltrion-aims-for-adalimumab-interchangeability-phase-3-results-for-ustekinumab-biosimilar EC Grants Celltrion Avastin Biosimilar Marketing Authorization https://www.centerforbiosimilars.com/view/ec-grants-celltrion-avastin-biosimilar-marketing-authorization BLA Accepted for Fresenius Kabi Tocilizumab Biosimilar https://www.centerforbiosimilars.com/view/bla-accepted-for-fresenius-kabi-tocilizumab-biosimilar…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S5 Ep4: Tools of the Trade: How McKesson’s Intrafusion Improves Infusion Center Efficiency, Biosimilar Utilization 15:30
15:30
Play Later
Play Later
Lists
Like
Liked15:30
Show notes: To learn more about McKesson’s Intrafusion, click here . To learn more about biosimilar storage concerns, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S5 Ep3: Not So Different: Biosimilars Oncology Roundup for July 2022—Podcast Edition 4:02
4:02
Play Later
Play Later
Lists
Like
Liked4:02
Show notes Written version of the roundup Phase 3 denosumab trial results Alvotech’s pharmacokinetics trial for denosumab Poster from the American Society of Clinical Oncology’s annual meeting Phase 1 pertuzumab trial Rituximab studies from the European Hematology Association Congress 2022 Survey on preparing patients and providers for switching to a biosimilar…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S5 Ep2: How Health Policies May Take Shape in a Post-Humira-Exclusive Adalimumab Market 12:48
12:48
Play Later
Play Later
Lists
Like
Liked12:48
To learn more about the hype regarding adalimumab biosimilars in the US, click here . To see which biosimilars have been approved by the FDA, click here . To read more on PBMs and their influence on biosimilar uptake, click here . To read Manolis’ 2016 paper, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S5 Ep1: Dr. Sonia Oskouei Discusses the US Launch of Byooviz, the First Ophthalmology Biosimilar 14:33
14:33
Play Later
Play Later
Lists
Like
Liked14:33
Show notes: To learn more about the US launch of Byooviz, click here . To read more about the anticipation for ophthalmology biosimilars, click here . To read more of Dr. Oskouei’s comments on “Round 2,” click here . To learn more about the EU approval of Byooviz, click here . To learn more about the Canadian approval of Byooviz, click here . To read more on the anticipation for aflibercept biosimilars, click here .…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S4 Ep22: Not So Different: Tactics for Increasing Patient and Provider Confidence in Biosimilars 4:36
4:36
Play Later
Play Later
Lists
Like
Liked4:36
To listen to part 1 of this podcast, click here . To listen to part 2 of this podcast, click here . To learn more about building patient confidence in biosimilars, click here . To learn more about how education can improve patient confidence, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S4 Ep21: Not So Different: How 1 Practice is Addressing Biosimilar Concerns Over Savings, Safety, and Efficacy 5:55
5:55
Play Later
Play Later
Lists
Like
Liked5:55
To listen to part 1 of this podcast, click here . To learn more about building physician confidence in biosimilars, click here . For more on how switching to biosimilars can impact budgets and savings, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S4 Ep20: Not So Different: How Biosimilar Companies Are Stepping Up Their Game to Compete Against Originators 3:55
3:55
Play Later
Play Later
Lists
Like
Liked3:55
Despite some biosimilars, including those for filgrastim, trastuzumab, and bevacizumab, achieving a greater US market share than their originators, other biosimilar categories, such as pegfilgrastim and infliximab, are still trailing behind. Some biosimilar companies are becoming more savvy, developing new ways to make a bigger statement in the market. We sat down with Kirollos Hanna, PharmD, the manager of Oncology Pharmacy at the University of Minnesota Medical Center, an associate editor for the Journal of the Advanced Practitioner in Oncology, and an assistant professor at the Mayo Clinic School of Medicine, to discuss what tactics biosimilar companies are using to better compete alongside originator manufacturers.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S4 Ep19: Not So Different: Gary Lyman, MD Details What Needs to Be Done to Ensure Physician Confidence in Biosimilars 16:23
16:23
Play Later
Play Later
Lists
Like
Liked16:23
A major barrier to biosimilar adoption is physician hesitancy when it comes to prescribing these agents, especially in the oncology space. Physicians often want more clinical or real-world evidence on the safety and efficacy of biosimilars compared with reference products in patients with cancer, for whom the stakes are high when choosing a therapeutic or supportive agent. Additionally, some clinicians worry about having to stock multiple biosimilars for a single reference product. These may require different storage conditions and increase the risk of administering the wrong agent, creating financial risk for the practice. We sat down with Gary Lyman, MD, MPH, an oncologist, hematologist, public health researcher, and long-time biosimilar advocate who has also helped develop guidelines in support of using biosimilars in the oncology space. We discussed what steps are needed to improve physician confidence in using biosimilars.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S4 Ep18: Not So Different: Should Biosimilar Variations Be Concerning? 4:49
4:49
Play Later
Play Later
Lists
Like
Liked4:49
To hear more from Paul on biosimilar issues, click here or here . To read about Paul’s insight on the current issues in the Indian biosimilar market, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S4 Ep17: Not So Different: What the Generics Industry Can Tell Us About the Future of Biosimilars 11:22
11:22
Play Later
Play Later
Lists
Like
Liked11:22
To learn more about the Hatch-Waxman Act, click here . To learn more about how biosimilars compare with the generics market, click here . To learn more about the challenges that both the biosimilars and generic markets face, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S4 Ep16: Not So Different: Axinn Patent Litigator Discusses Implications of ACA Ruling 11:47
11:47
Play Later
Play Later
Lists
Like
Liked11:47
For background reading on the ACA case, read about the June 2021 ruling here , and for background on the withdrawal of the Department of Justice from the plaintiffs’ side of the suit, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S4 Ep15: Not So Different: How Henlius is Making Its Mark on the Global Biosimilar Industry 9:35
9:35
Play Later
Play Later
Lists
Like
Liked9:35
To hear more comments from Ping Cao, click here . To learn more about Henlius’ development plans, click here . To learn more about Henlius’ approval for their adalimumab biosimilar, click here . To learn more about PD-1 inhibitors, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S4 Ep14: How Pharmacists Can Help Boost Biosimilar Uptake 9:30
9:30
Play Later
Play Later
Lists
Like
Liked9:30
To learn more about Sonia’s work, click here . To learn more about pharmacists’ role in promoting biosimilars, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S4 Ep13: The Fight to Align Payer Preferences With Community Oncology 10:31
10:31
Play Later
Play Later
Lists
Like
Liked10:31
To learn more about payer preferences, click here . To see how Minnesota legislators are working to override payer preferences, click here . For more on payer influence on prescribing patterns, click here . For more on NCCN’s biosimilar work, click here . You can also check out part 1 and part 2 of this series. To check out our Biosimilar Approvals navigator, click here .…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S4 Ep12: What’s Stopping Physicians From Prescribing Biosimilars? 18:56
18:56
Play Later
Play Later
Lists
Like
Liked18:56
To learn more about struggles regarding physician decisions on biosimilars, click here . For more on payer influence on prescribing patterns, click here . For more on NCCN’s biosimilar work, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S4 Ep11: How to Improve Perception Hurdles to Biosimilar Adoption 18:03
18:03
Play Later
Play Later
Lists
Like
Liked18:03
For more on biosimilar perception, click here . For more on NCCN’s biosimilar work, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S4 Ep10: Has Brexit Hindered Biosimilar Development? 6:07
6:07
Play Later
Play Later
Lists
Like
Liked6:07
To learn more about Brexit's impact on the biologics industry, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S4 Ep9: Dr Juliette Petit: How Nurses Prevent Nocebo Effect in Biosimilar Switching 11:50
11:50
Play Later
Play Later
Lists
Like
Liked11:50
Learn more about Dr Petit’s study .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S4 Ep8: Minnesota Legislator Discusses Bill to Broaden Biosimilar Coverage 10:52
10:52
Play Later
Play Later
Lists
Like
Liked10:52
To learn more about the bill, click here . To read the bill’s official text, click here . To learn more about payer formulary preferences, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S4 Ep7: Goodwin Attorneys Discuss Updates to Biosimilars Litigation Guide 11:11
11:11
Play Later
Play Later
Lists
Like
Liked11:11
To learn more about Valenti and Cerwicki's updated guide, click here . To learn more about adalimumab patent disputes, click here . To learn more about the future state for the adalimumab market, click here . To take our quiz on adalimumab, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S4 Ep6: Anar Dossa Discusses Success and Savings With British Columbia’s Biosimilars Initiative 12:23
12:23
Play Later
Play Later
Lists
Like
Liked12:23
To learn more about phase 3 of the BC Biosimilars Initiative, click here . To learn more about recent biosimilar launches in Canada, click here or here . To learn more about biosimilar switches in Canada, click here . To learn more about other Canadian province’s biosimilar plans, click here . To learn more about Pacific Blue Cross’s success with the program, click here .…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S4 Ep5: Sarfaraz Niazi, PhD Discusses Market Projections For High-Concentration Adalimumab Biosimilars 13:20
13:20
Play Later
Play Later
Lists
Like
Liked13:20
To learn more about Celltrion's EU approval, click here . To learn more about Alvotech’s high concentration adalimumab, click here . To learn more about high-concentration citrate-free adalimumab products, click here . To learn about the patent dance, click here . For more in adalimumab news, click here or here .…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S4 Ep4: Steven Lucio Discusses BI’s Citizen Petition and the Current Status of Biosimilars 12:45
12:45
Play Later
Play Later
Lists
Like
Liked12:45
To learn more about BI’s citizen petition, click here . To hear more from Steven Lucio, PharmD, BCPS, click here . To learn more about Vizient, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S4 Ep3: The Race to the Top: Does China Have What it Takes? 5:00
5:00
Play Later
Play Later
Lists
Like
Liked5:00
You can read more about China’s market by clicking here or here . For information on Bio-Thera, click here . For information on Shanghai Henlius Biotech, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S4 Ep2: Why You Should Keep Your Eye on Ophthalmology Biosimilars 7:57
7:57
Play Later
Play Later
Lists
Like
Liked7:57
To read more on Dr Oskouei's contributor piece, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S4 Ep1: Charles Bennett, MD, PhD, Discusses Why the FTC Needs to Join the Effort to Improve the Biosimilar Market 9:29
9:29
Play Later
Play Later
Lists
Like
Liked9:29
To read more about Bennett's study, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep32: Sean McGowan on What’s in Store for Biosimilars in 2021 and Beyond 10:41
10:41
Play Later
Play Later
Lists
Like
Liked10:41
To watch the full first part of this interview, click here . To watch part 2 of this interview, click here . To watch part 3 of this interview, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep31: A Trio of Experts’ Take on What Needs to Change to Boost Biosimilar Adoption 8:57
8:57
Play Later
Play Later
Lists
Like
Liked8:57
To learn more about biosimilar barriers, click here . To learn more about the US Oncology Network, click here . To learn more about McKesson, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep30: Kathy Oubre On What Practices Can Learn About the Benefits of Implementing Biosimilars 9:09
9:09
Play Later
Play Later
Lists
Like
Liked9:09
To learn more about the COA's virtual Payer Exchange Summit on Oncology Payment Reform, click here . To learn more about Pontchartrain Cancer Center, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep29: Steven C. Hill, PhD, Discusses Rebates and Specialty Drug Spending 12:26
12:26
Play Later
Play Later
Lists
Like
Liked12:26
To learn more about this study, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep28: Nancy Globus, PharmD, on Whether Comparative Efficacy Trials are Necessary 7:46
7:46
Play Later
Play Later
Lists
Like
Liked7:46
To learn more about the study mentioned in this podcast, click here . To learn more about the United Kingdom's stance on comparative efficacy trials, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep27: Kathy Oubre on What Oncology Practices Lacked During the Pandemic 14:17
14:17
Play Later
Play Later
Lists
Like
Liked14:17
To learn more about COVID-19’s impact on biosimilars, check out our ebook here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep26: Kanika Monga, MD, and Angus Worthing, MD, Discuss ACR Survey on Biosimilars and COVID-19 12:09
12:09
Play Later
Play Later
Lists
Like
Liked12:09
To learn more about the ACR’s survey, click here . To learn more about COVID-19’s impact on biosimilars, check out our ebook here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep25: Wayne Winegarden, PhD, On Why Importing Drugs From Canada Is a Bad Idea 8:59
8:59
Play Later
Play Later
Lists
Like
Liked8:59
To read more on Wayne’s thoughts of this plan, click here . To learn more about the Safe Importation Action Plan, click here . To learn more about President Trump’s executive orders, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep24: Julie Kennerly-Shah, PharmD, on How Biosimilars Can Help Curb COVID-19's Impact 10:55
10:55
Play Later
Play Later
Lists
Like
Liked10:55
To learn more about COVID-19's impact on biosimilars, click here . To learn more about biosimilar education, click here . To learn more about step therapy, click here . To learn more about payer interference on preferred drugs, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep23: Rep Grothman on His Bill to Make Biosimilar Insulins Interchangeable 9:03
9:03
Play Later
Play Later
Lists
Like
Liked9:03
To learn more about HR 8190, click here . To learn more about the regulatory transition of insulin under the BPCIA, click here . To learn more about interchangeability designations, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep22: Alex Moulson on How Companies Choose Which Biosimilars to Produce 9:54
9:54
Play Later
Play Later
Lists
Like
Liked9:54
To check out more of our coverage of Polpharma Biologics, click here . To learn more about Polpharma's natalizumab clinical trial, click here . To learn about Polpharma Biologics recent integration efforts, click here . To learn more about Polpharma Biologics, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep21: Cheryl Larson on How Employers Can Get Biosimilars Added to Their Health Plan 10:37
10:37
Play Later
Play Later
Lists
Like
Liked10:37
To learn more about MBGH's call to action for employers, click here . To learn more about MBGH's biosimilars report, click here . To learn more about Midwest Business Group on Health, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep20: Jonathan Sweeting on Aybintio's European Approval 9:14
9:14
Play Later
Play Later
Lists
Like
Liked9:14
To learn more about the EC's approval of Aybintio, click here . To learn more about Samsung Bioepis, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep19: Nancy Globus, PharmD, on the Effect of Biosimilar Suffixes 6:14
6:14
Play Later
Play Later
Lists
Like
Liked6:14
To learn more about biosimilar naming, click here . Click here to learn more about the ACMA.
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep18: Carter Thorne, MD, Discusses Biosimilar Switching in Canada 7:54
7:54
Play Later
Play Later
Lists
Like
Liked7:54
To learn more about Canadian switching policies, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep17: Sizing Up European Biosimilar Competition 9:32
9:32
Play Later
Play Later
Lists
Like
Liked9:32
To check out the scorecard, click here . To learn more about Medicines for Europe, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep16: Dorothy McCabe, PhD, Discusses How to Combat Biosimilar Misinformation 7:50
7:50
Play Later
Play Later
Lists
Like
Liked7:50
To learn more about the opinion piece McCabe co-authored, click here . To learn more about Boehringer Ingelheim, visit boehringer-ingelheim.com .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep15: Rathore: What Biosimilar Developers Can Learn From Application Failures 7:46
7:46
Play Later
Play Later
Lists
Like
Liked7:46
To learn more about the study, click here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep14: Byoungseo Choi on Celltrion's Biosimilar Goals For 2030 8:57
8:57
Play Later
Play Later
Lists
Like
Liked8:57
To learn more about Celltrion Healthcare, visit celltrionhealthcare.com . You can learn more about the testing of Celltrion's infliximab biosimilar for the treatment of COVID-19 here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep13: Ryan Haumschild, PharmD, Discusses Plan to Increase Biosimilar Utilization 4:15
4:15
Play Later
Play Later
Lists
Like
Liked4:15
To learn more about Emory Healthcare, visit emoryhealthcare.org .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep12: Dr Jing Chao Discusses Knowledge Gaps and the Future for Biosimilar Insulins 5:52
5:52
Play Later
Play Later
Lists
Like
Liked5:52
To learn more about the study, read our full coverage of it here .
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep11: Joe Fuhr, PhD Discusses His Predictions for the Growing Biosimilar Market 3:48
3:48
Play Later
Play Later
Lists
Like
Liked3:48
The United States’ slow start to biosimilar uptake has manifested in a number of ways, from delayed launches due to patent disputes to anticompetitive practices creating a distrust of biosimilars among patients and physicians. However, some experts still see hope for the industry. We sat down with Joe Fuhr, PhD, professor emeritus of economics at Widener University in Chester, Pennsylvania, and an expert on antitrust health economics and pharmacoeconomics to discuss the current state of the biosimilar landscape and what he sees going forward.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep10: Nick Mitrokostas Discusses New Biosimilar Approval and Outlooks for 2020 5:28
5:28
Play Later
Play Later
Lists
Like
Liked5:28
To learn more about the approval of Nyvepria, check out our article on it here . To learn more about Goodwin Proctor LLP, visit goodwinlaw.com/
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep9: Christine Simmon Discusses AAM Efforts for Biosimilar Legislation 6:24
6:24
Play Later
Play Later
Lists
Like
Liked6:24
To learn more about AAM, visit accessiblemeds.org
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep8: Biosimilar Law Experts Discuss Potential Bills and Chances for Passage 15:54
15:54
Play Later
Play Later
Lists
Like
Liked15:54
To learn more about Venable Fitzpatrick, visit venable.com . To learn more about all of the bills that were discussed, visit congress.gov
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep7: April Breyer Menon Discusses 2 Potential Bills to Aid Biosimilar Uptake 12:49
12:49
Play Later
Play Later
Lists
Like
Liked12:49
It’s no secret that the US biosimilar industry has had a slow start in terms of uptake, but much of that setback is due to barriers caused by originator manufacturers taking advantage of current legislation. Although, the Hatch-Waxman Act and the Biologic Price Competition and Innovation Act (BPCIA) established pathways to approval for both generic drugs and biosimilars, there is still much legislative work to be done in order to truly reap the benefits of biosimilars. We sat down with April Breyer Menon, an expert on biosimilar patent law and founder of April Breyer Consulting in Chicago, Illinois, to discuss potential legislation such as The Hatch-Waxman Integrity Act and the Stop Stalling Act that would address barriers to biosimilar market entry.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep6: Noelle Sunstrom and the Potential Growth for NeuClone 3:32
3:32
Play Later
Play Later
Lists
Like
Liked3:32
To learn more about NeuClone, visit https://neuclone.com/
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep5: Dr Sang-Jin Pak Talks Biosimilar Market Stability 2:41
2:41
Play Later
Play Later
Lists
Like
Liked2:41
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep4: Dr. Sang-Jin Pak Talks Biosimilar Markets: US vs Europe 3:25
3:25
Play Later
Play Later
Lists
Like
Liked3:25
In April 2020, Samsung Bioepis launched Ontruzant, a biosimilar for trastuzumab, in the US market, in partnership with Merck. The company launched the same drug in Europe in 2018, and it was the first trastuzumab biosimilar in Europe. This earlier release of biosimilars in Europe is not an anomaly, as Europe has had a much easier time developing and launching biosimilars than the US thanks to their decade-long head start in the industry. We sat down with Dr. Sang-Jin Pak, the executive vice president of Samsung Bioepis’ Commercial Division to discuss the differences between the US and Europe.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep3: "Not So Different": How the BPCIA Transition Will Impact Biosimilar Uptake 10:36
10:36
Play Later
Play Later
Lists
Like
Liked10:36
On March 23rd, 2020, the transition under the Biologics Price Competition and Innovation Act was complete, allowing products formerly classified as “small-molecule” drugs, including all insulin products, to be approved under the biologics regulatory pathway. This week on the podcast, we’re speaking with executive director of the Biologics and biosimilars collective intelligence consortium (also known as the BBCIC) , Cate Lockhart, about the acceptance process for biosimilars in the United States, what BBCIC is doing to help the market develop, and how this new transition will impact the market and uptake efforts.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep2: Employers Advocate for Lower Drug Costs Through Biosimilars 17:41
17:41
Play Later
Play Later
Lists
Like
Liked17:41
N
Not So Different: A Podcast from The Center for Biosimilars

1 S3 Ep1: Goodwin Attorneys Give a Look at Biosimilar Litigation 21:43
21:43
Play Later
Play Later
Lists
Like
Liked21:43
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep32: The Year in US Regulatory Activity for Biosimilars 6:27
6:27
Play Later
Play Later
Lists
Like
Liked6:27
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep31: At the American College of Rheumatology, a UK Perspective on Biosimilars 7:30
7:30
Play Later
Play Later
Lists
Like
Liked7:30
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep30: AmerisourceBergen’s Sean McGowan Takes a Closer Look at US Biosimilar Launches 16:49
16:49
Play Later
Play Later
Lists
Like
Liked16:49
With us on the podcast to talk about recent and upcoming biosimilar launches is Sean McGowan, senior director of biosimilars at AmerisourceBergen. McGowen spoke with us about what the US biosimilars market needs now in order to thrive, and tells us which developments he'll be watching closely in 2020.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep29: Celltrion Breaks New Ground With a Subcutaneous Biosimilar Infliximab 10:03
10:03
Play Later
Play Later
Lists
Like
Liked10:03
Last month, the European Commission authorized a subcutaneously administered formulation of biosimilar infliximab CT-P13 for the treatment of rheumatoid arthritis. When the drug launches in the European Union, it will be first infliximab to be available in a subcutaneous formulation. This week on the podcast, we’re speaking about this new product with Mike An, head of the sales and operations division at Celltrion Healthcare.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep28: Biosimilar Business Updates From the Month of November 8:19
8:19
Play Later
Play Later
Lists
Like
Liked8:19
This week on the podcast, we’re rounding up the top biosimilar business stories of November 2019.
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep27: Is There a Role for Biosimilars in Value-Based Models? 18:58
18:58
Play Later
Play Later
Lists
Like
Liked18:58
As fee-for-service models give way to value-based healthcare delivery models, US providers and patients alike can hopefully forward to lower healthcare costs, increased quality of care, and improved outcomes. But what role will biosimilars have to play in value-based care? This week on the podcast, we're speaking with Jeffrey Scott MD, chief medical officer of Integra Connect, a company that uses cloud-based technologies and services that help specialty care providers optimize their performance in the ongoing shift to value-based models. Scott spoke with us about value-based contracting in the biosimilars context.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep26: HealthyWomen Wants to Educate US Women About Biosimilars 12:49
12:49
Play Later
Play Later
Lists
Like
Liked12:49
In October of this year, the nonprofit organization HealthyWomen, a group that seeks to educate women to make informed choices about their health, hosted its first Biosimilars and Women’s Health Science and Policy Forum. This week on the podcast, we’re speaking with one of the presenters from that meeting, Lisa Kennedy Sheldon, PhD, APRN, AOCNP, FAAN.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep25: AARP Says High Prescription Drug Prices Will Impact All Americans 7:45
7:45
Play Later
Play Later
Lists
Like
Liked7:45
Back in September, AARP, issued its latest Rx Price Watch report, which highlighted the problem of skyrocketing drug costs; it found the retail prices for widely used drugs increased well above the rate of inflation, and that’s a troubling trend for Medicare beneficiaries. This week on the podcast, we’re speaking with one of the authors of that report, Leigh Purvis, MPA, who says that the problem of high costs will eventually impact all Americans.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep24: What's New in Biosimilars in Gastroenterology 8:01
8:01
Play Later
Play Later
Lists
Like
Liked8:01
With new research being presented, and with new biosimilars in the pipeline that target inflammatory bowel disease, October was a notable month for biosimilars in the gastroenterology space. This week on the podcast, we’re rounding up the top developments in gastroenterology for the month of October 2019.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep23: Strategies for Biosimilar Developers in a Litigious US Landscape 18:54
18:54
Play Later
Play Later
Lists
Like
Liked18:54
In August of this year, the US District Court for the District of New Jersey ruled in favor of Amgen in a long-running patent litigation concerning Sandoz’s biosimilar etanercept, Erelzi. As a result of that decision, biosimilar etanercept appears to be on a lengthy hold in the US market, and that has a number of biosimilar stakeholders concerned. This week on the podcast, we’re speaking with Rick Lozano, vice president of Biosimilars and Integrated Business Development for AmerisourceBergen. We discuss the ruling in the case, its potential impacts on the healthcare system, and what drug makers can do now to help educate other stakeholders about biosimilars and improve uptake.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep22: Are We Ready for Biosimilar Rituximab in the United States? 11:31
11:31
Play Later
Play Later
Lists
Like
Liked11:31
It’s widely expected that the United States will see launches of one or both of the FDA-approved biosimilars, Ruxience and Truxima, in the coming months, but just how ready is the United States to bring these products to the clinic, especially given the fact that subcutaneously administered reference rituximab has taken on such a key place in clinical practice, and given the fact that both biosimilars have so-called “skinny labels” because of issues related to intellectual property and exclusivities? Over the past year, we’ve had the opportunity to explore these questions and more with a variety of experts in the oncology field. This time on the podcast, we’re rounding up some of the key insights they’ve shared.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep21: What Have We Learned So Far About US Oncology Biosimilars? 20:09
20:09
Play Later
Play Later
Lists
Like
Liked20:09
Among the biggest biosimilars news of this year was the launch of the first 2 anticancer biosimilars; stakeholders have been eager to see whether these products can jumpstart what has been described by some as a sluggish US market for biosimilar products. This week on the podcast, we're speaking with an expert who's sharing her insight into these developments in the oncology space. Christina Corridon, MPH, MBA, is a principal at the professional services firm ZS Associates, where she is a leader in ZS' oncology practice and leads their biosimilars vertical. Christina joined us to talk about the state of play in the US biosimilars market, what we can learn from ongoing experience, and how sustainable the US market for biosimilars may be today.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep20: OneOncology Gives a Closer Look at Its Biosimilar Adoption 10:18
10:18
Play Later
Play Later
Lists
Like
Liked10:18
The question of whether anticancer biosimilars will achieve strong uptake in the United States, and whether they will produce much-needed cost savings, is one that has pervaded the conversation about US biosimilars for some time. Shortly after Amgen launched the first 2 such agents, biosimilar trastuzumab and bevacizumab, OneOncology, a group that comprises 4 large community oncology practices and 100 sites of care, announced that it had made those 2 biosimilars preferred agents. This week on the podcast, we’re speaking with Jeffrey Patton, MD, chief executive officer of Tennessee Oncology, a partner practice of OneOncology, and the President of Physician Services for OneOncology. Patton shares with us the rationale for the adoption of biosimilars, how patients are responding, and lessons learned.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep19: Where Are We Headed With Oncology Biosimilars? Vizient Weighs In 17:11
17:11
Play Later
Play Later
Lists
Like
Liked17:11
In its semiannual drug pricing forecast, healthcare performance company Vizient said that biosimilars will be a key part of combatting rising spending on drugs. This week on the podcast, we're speaking with Steven Lucio, PharmD, BCPS, associate vice president of clinical solutions and pharmacy program development at Vizient, on how oncology biosimilars are poised to make an impact.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep18: How a Value-Based Pathway Led to Increased Biosimilar Use 12:28
12:28
Play Later
Play Later
Lists
Like
Liked12:28
It's no secret that biosimilars that treat inflammatory diseases have struggled to gain ground in the United States, but given the benefits that biosimilars can offer, some physicians are taking matters into their own hands with concerted efforts to bring biosimilars to the clinic. This week on the podcast, we're speaking with Colin C. Edgerton, MD. He's one of the founding members of Articularis Health Group, which has created a value-based rheumatoid arthritis treatment pathway that has boosted biosimilar use.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep17: What's Next for Drug Pricing After Withdrawal of the Rebate Rule? 17:38
17:38
Play Later
Play Later
Lists
Like
Liked17:38
In July, the Trump administration withdrew its proposal to block rebates and discounts given by drug makers to pharmacy benefit managers, Part D plans, and Medicaid managed care organizations. HHS previously said that the rule would counteract incentives behind higher list prices. Withdrawal of the rule was a discouraging development for many physicians who hoped that the proposal could give relief to their patients at the pharmacy counter. This week on the podcast, we’re speaking to one such physician, Madelaine Feldman, MD.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep16: The Biosimilars Council Says Patent Abuses Are Costing Biosimilar Savings 18:17
18:17
Play Later
Play Later
Lists
Like
Liked18:17
The Biosimilars Council, a part of the Association for Accessible Medicines, recently issued a white paper in which it condemns abuses of the patent system that delay biosimilar competition. The group estimates that the financial impact of these delays has cost the US healthcare system $7.5 billion in lost savings since 2015. This week on the podcast, we’re speaking with Christine Simmon, executive director of the Biosimilars Council, about the paper, about patent thickets, and about what policy issues the organization wants to see addressed to move the needle on biosimilars.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep15: What Did the First Half of 2019 Hold for Biosimilars? 11:03
11:03
Play Later
Play Later
Lists
Like
Liked11:03
At the beginning of this year, we spoke with Laura Joszt, associate editorial director and the host of The American Journal of Managed Care’s podcast, Managed Care Cast, about where biosimilars stood at the end of 2018. Now, halfway through the year, we’re continuing that conversation with a look at how biosimilars have fared so far in 2019.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep14: The Biosimilars Forum Wants to Save the Healthcare System Billions 22:21
22:21
Play Later
Play Later
Lists
Like
Liked22:21
Industry group the Biosimilars Forum recently put forth 3 policy proposals that it says could save the US healthcare system billions of dollars. This week on the podcast, we’ve invited the forum to tell us more about their proposals and other policy issues related to biosimilars. Joining us this week are Juliana Reed and Molly Burich. Reed is the vice president corporate affairs, global biosimilars lead at Pfizer, and is also president of the forum. Burich is director of public policy, biosimilars, and reimbursement at Boehringer Ingelheim, and an officer in the forum.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep13: What's Holding Back Biosimilars? It May Not Be Pay-for-Delay Deals 23:28
23:28
Play Later
Play Later
Lists
Like
Liked23:28
While pay-for-delay issues have been big news on Capitol Hill recently, some experts have questions about whether these kinds of settlements are really at the heart of delayed biosimilar competition, and they offer alternative ways to think about—and to fix—the problem. This week on the podcast, we’re speaking with 2 such experts, Imron Aly, JD, and Joel Wallace, JD. Both are partners at Schiff Hardin LLP and have extensive experience with Hatch-Waxman and biosimilars intellectual property issues.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep12: A Regulatory Attorney Shares His Take on Interchangeability 15:18
15:18
Play Later
Play Later
Lists
Like
Liked15:18
Recently, the FDA released its long-anticipated final guidance on demonstrating interchangeability, and developers have been grappling with how the guidance will impact them. This week on the podcast, we're speaking with regulatory attorney James Shehan, JD, chair of regulatory practice at Lowenstein Sandler, LLP. In a prior role, Shehan had a hand in crafting the language that became the Biologics Price Competition and Innovation Act, which set forth the legal standard for interchangeability. Shehan discusses what the newly released guidance means for developers, what he thinks about the upcoming transition of insulins to regulation as biologics, and his view on the potential for interchangeable insulin biosimilars.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep11: A Look Ahead to Biosimilar Insulin 24:11
24:11
Play Later
Play Later
Lists
Like
Liked24:11
Amid growing concern about the skyrocketing cost of insulin in the United States, the FDA held a public hearing this month about biosimilar insulins. This week on the podcast, we caught up with one of the experts who testified at the hearing: Steven Lucio, PharmD, BCPS, associate vice president of clinical solutions and pharmacy program development at Vizient. He shared his thoughts with us on biosimilar insulins, interchangeability, biosimilar suffixes, and what milestones lie ahead as the United States approaches its 2020 transition of insulins to regulation as biologics.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep10: A Look at Biosimilar Education Among European Oncologists 18:16
18:16
Play Later
Play Later
Lists
Like
Liked18:16
The cost of cancer care is on the rise worldwide, and biosimilars present one option for bringing down costs. However, those savings depend on adoption and use of biosimilars, and hesitancy to use these agents on the part of prescribers has been well documented. One newly published study reported on a survey conducted among European Society for Medical Oncology (ESMO) members and attendees of the 2017 ESMO Congress in Madrid, Spain, concerning biosimilars. This week, we’re speaking with the study’s lead author, Rosa Giuliani, MD. She’s a medical oncologist at The Christie Hospital, Manchester, United Kingdom, and Chair of the ESMO Global Policy Committee.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep9: Is It Time to Give Up On Biosimilars? 23:19
23:19
Play Later
Play Later
Lists
Like
Liked23:19
In a 2-part proposal published on the Health Affairs blog, a team of authors argued that efforts to induce lower prices through competition via biosimilars will inevitably fail. Instead, they write, prices for innovator biologics should be regulated by the US government after patent expiry.This week on the podcast, we’re talking with Mark Trusheim, MS, one of the authors of the proposal.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep8: Drug Pricing in the United States: a Conversation with Robin Feldman 22:44
22:44
Play Later
Play Later
Lists
Like
Liked22:44
Recent months have seen a variety of proposals to bring down the cost of prescription drugs, but will any of them have staying power? This week, senior editor Allison Inserro speaks with Robin Feldman, professor at the University of California, Hastings, College of the Law, and author of the new book Drugs, Money, and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep7: The Community Oncology Perspective on Drug Pricing Proposals and Biosimilars 15:01
15:01
Play Later
Play Later
Lists
Like
Liked15:01
The recent weeks and months have seen a number of policy proposals from the Trump administration that impact community oncologists. On this week's podcast, Laura Joszt, associate editorial director of The Center for Biosimilars®, caught up with Ted Okon, MBA, executive director of the Community Oncology Alliance.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep6: Addressing Misinformation on Biosimilars 13:55
13:55
Play Later
Play Later
Lists
Like
Liked13:55
Last year, biosimilar developer Pfizer submitted a citizen petition to the FDA in which it called on the agency to issue guidance clarifying how drug sponsors can communicate about biosimilars. After the petition was filed, The Center for Biosimilars® invited an expert group of stakeholders to discuss misinformation about biosimilars as well as what steps are necessary to root out and address misinformation. This time on the podcast, we’re sharing a portion of that discussion with our listeners.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep5: Meet the Nonprofit Taking on Generic Drug Shortages 10:01
10:01
Play Later
Play Later
Lists
Like
Liked10:01
This week on the podcast, we're speaking with Civica Rx’s Heather Wall. She’s the organization’s chief commercial officer, and was recently named one of Modern Heatlhcare’s women leaders to watch.
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep4: "Not so Different:" The Supreme Court and US Biosimilars 20:31
20:31
Play Later
Play Later
Lists
Like
Liked20:31
Those who follow the biosimilars space closely are aware that, in the context of the US market, legal concerns regarding biosimilars can be just as regulatory ones in informing how drug makers do business. One recent case that impacts on upon the biosimilars market was recently heard before the before the United States Supreme Court, and the outcome of the case will potentially impact drug makers seek patent protection for various aspects of their products. In order to take a deeper dive into the case, and hear an expert perspective on its far-reaching impacts, this week, we’re speaking with Ha Kung Wong, JD, a partner at Venable LLP and an advisory board member for The Center for Biosimilars.®…
N
Not So Different: A Podcast from The Center for Biosimilars

1 S2 Ep3: Where Do We Stand With Provider Education on Biosimilars? 9:07
9:07
Play Later
Play Later
Lists
Like
Liked9:07
Recently, a new systematic review evaluating US and European provider awareness of biosimilars found a persistent lack of education on both sides of the Atlantic. This week, The Center for Biosimilars® is speaking with Sonia T. Oskouei, PharmD, one of the authors of the review, about the findings.
N
Not So Different: A Podcast from The Center for Biosimilars

2018 was a banner year for biosimilars, both in the United States and abroad. In this episode of the podcast, Laura Joszt, associate editorial director of The American Journal of Managed Care, interviews The Center for Biosimilars’ senior editor, Kelly Davio, about the key developments in biosimilars last year.…
N
Not So Different: A Podcast from The Center for Biosimilars

This season on the podcast, we’re bringing you the news you need to stay up to date on the key issues facing biosimilars. In this episode, we’ll talk about what’s new in biosimilar regulation.
N
Not So Different: A Podcast from The Center for Biosimilars

1 Episode 10: The Patient Perspective on Biosimilars 10:57
10:57
Play Later
Play Later
Lists
Like
Liked10:57
Recently, Louis Tharp, the cofounder and executive director of the patient advocacy organization the Global Healthy Living Foundation, visited our studios in New Jersey to talk about how high drug costs impact patients with rheumatic diseases, and how biosimilars can be part of the solution. What follows is a portion of our discussion about biologics, biosimilars, and the patient's viewpoint.…
N
Not So Different: A Podcast from The Center for Biosimilars

1 Episode 9: Biosimilars and Expanded Access to Cancer Treatment 11:31
11:31
Play Later
Play Later
Lists
Like
Liked11:31
Among the great promises of biosimilar therapies is their ability to not only reduce costs for patients and healthcare systems, but to make room in budgets for spending on other high-cost drugs, especially in treating cancer. This week on “Not So Different,” our guest is Ali McBride, PharmD, MS, BCPS. McBride is pharmacist who serves as the Clinical Coordinator for Hematology and Oncology at The University of Arizona Cancer Center. He’s also the lead author of a recent study that showed that using biosimilar filgrastim can expand patients’ access to treatment with obinutuzumab.…
N
Not So Different: A Podcast from The Center for Biosimilars

This week on the podcast, we’re pleased to welcome our guest, Leigh Purvis, MPA. Purvis is the director of health services research at AARP’s public policy institute. Her work focuses on a variety of prescription drug and mental health-related issue, with an emphasis on prescription drug pricing, biologic drugs, and prescription drug coverage under Medicare. Purvis joined us by phone to talk about the challenges that Medicare beneficiaries face with respect to obtaining and paying for their biologic drugs, and about the policies that AARP hopes to see implemented in the days ahead.…
N
Not So Different: A Podcast from The Center for Biosimilars

This week, we're delving into the world of supportive care and anticancer biosimilars with an oncology expert, Robert M. Rifkin, MD, FACP.
N
Not So Different: A Podcast from The Center for Biosimilars

1 Episode 6: The Nebraska Rheumatology Society 10:31
10:31
Play Later
Play Later
Lists
Like
Liked10:31
Today, we're talking about state-level legislation concerning the substitution of interchangeable biosimilars, and how 1 specific piece of biosimilars-focused legislation led to the formation of the Nebraska Rheumatology Society. Our guest this week is Marcus Snow, MD, a rheumatologist at the University of Nebraska Medical Center, and assistant professor of rheumatology at the University of Nebraska.…
N
Not So Different: A Podcast from The Center for Biosimilars

Episode 5: Policy and Biosimilars by The Center for Biosimilars
N
Not So Different: A Podcast from The Center for Biosimilars

1 Episode 4: Creating a Vibrant Biosimilars Market 13:41
13:41
Play Later
Play Later
Lists
Like
Liked13:41
Episode 4: Creating a Vibrant Biosimilars Market by The Center for Biosimilars
N
Not So Different: A Podcast from The Center for Biosimilars

Episode 3: Pricing by The Center for Biosimilars
N
Not So Different: A Podcast from The Center for Biosimilars

Episode 2: Nonmedical Switching by The Center for Biosimilars
N
Not So Different: A Podcast from The Center for Biosimilars

Episode 1: Interchangeability by The Center for Biosimilars
Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.